Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes — NEJM

  • 0

Original Article from The New England Journal of Medicine — Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Source: Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes — NEJM

Delivery of Health Care / Diabetes Education / Diabetes Management / Epidemiology / Limb Salvage Teams / Peripheral Arterial Disease / Vascular Support

Author

PV Mayer

Dr. Perry Mayer is the Medical Director of The Mayer Institute (TMI), a center of excellence in the treatment of the diabetic foot. He received his undergraduate degree from Queen’s University, Kingston and medical degree from the Royal College of Surgeons in Ireland.

WebsiteAll posts

Add Comment

Privacy Policy